Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What Ails Coverage With Evidence Development? MedPAC Discusses Issues

This article was originally published in The Gray Sheet

Executive Summary

The Medicare Payment Advisory Committee has begun exploring whether CMS needs more help in fostering its coverage-with-evidence-development program

You may also be interested in...



CMS Coverage-With-Evidence-Development Policy Could Face Revamp

CMS is taking comments through Jan. 6 on implementation of CED policies as part of national coverage determinations, how CED impacts Medicare beneficiaries and how new approaches might maximize benefits.

Former Medicare Officials Urge Reforms To Coverage Process

Four former CMS officials are calling for dramatic changes to Medicare coverage policy that would allow the agency to consider cost in its coverage decision-making, require prior authorization for technologies to ensure compliance with national coverage policies and devote more government resources to clinical research specific to Medicare needs.

Former Medicare Officials Urge Reforms To Coverage Process

Four former CMS officials are calling for dramatic changes to Medicare coverage policy that would allow the agency to consider cost in its coverage decision-making, require prior authorization for technologies to ensure compliance with national coverage policies and devote more government resources to clinical research specific to Medicare needs.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel